Effects  ||| S:0 E:8 ||| NNS
of  ||| S:8 E:11 ||| IN
leucine  ||| S:11 E:19 ||| NN
or  ||| S:19 E:22 ||| CC
whey  ||| S:22 E:27 ||| JJ
protein  ||| S:27 E:35 ||| NN
addition  ||| S:35 E:44 ||| NN
to  ||| S:44 E:47 ||| TO
an  ||| S:47 E:50 ||| DT
oral  ||| S:50 E:55 ||| JJ
glucose  ||| S:55 E:63 ||| JJ
solution  ||| S:63 E:72 ||| NN
on  ||| S:72 E:75 ||| IN
serum  ||| S:75 E:81 ||| JJ
insulin ||| S:81 E:88 ||| NN
,  ||| S:88 E:90 ||| ,
plasma  ||| S:90 E:97 ||| JJ
glucose  ||| S:97 E:105 ||| NN
and  ||| S:105 E:109 ||| CC
plasma  ||| S:109 E:116 ||| JJ
amino  ||| S:116 E:122 ||| JJ
acid  ||| S:122 E:127 ||| NN
responses  ||| S:127 E:137 ||| NNS
in  ||| S:137 E:140 ||| IN
horses  ||| S:140 E:147 ||| NNS
at  ||| S:147 E:150 ||| IN
rest  ||| S:150 E:155 ||| NN
and  ||| S:155 E:159 ||| CC
following  ||| S:159 E:169 ||| VBG
exercise  ||| S:169 E:178 ||| NN
Providing  ||| S:178 E:188 ||| NNP
protein  ||| S:188 E:196 ||| NN
or  ||| S:196 E:199 ||| CC
amino  ||| S:199 E:205 ||| JJ
acid  ||| S:205 E:210 ||| NN
mixtures  ||| S:210 E:219 ||| NNS
in  ||| S:219 E:222 ||| IN
combination  ||| S:222 E:234 ||| NN
with  ||| S:234 E:239 ||| IN
glucose  ||| S:239 E:247 ||| VBG
to  ||| S:247 E:250 ||| TO
post  ||| S:250 E:255 ||| VB
exercise  ||| S:255 E:264 ||| NN
in  ||| S:264 E:267 ||| IN
man  ||| S:267 E:271 ||| NN
has  ||| S:271 E:275 ||| VBZ
resulted  ||| S:275 E:284 ||| VBN
in  ||| S:284 E:287 ||| IN
increases  ||| S:287 E:297 ||| NNS
in  ||| S:297 E:300 ||| IN
the  ||| S:300 E:304 ||| DT
post  ||| S:304 E:309 ||| NN
feeding  ||| S:309 E:317 ||| VBG
insulin  ||| S:317 E:325 ||| NN
response  ||| S:325 E:334 ||| NN
and  ||| S:334 E:338 ||| CC
in  ||| S:338 E:341 ||| IN
muscle  ||| S:341 E:348 ||| NN
glycogen  ||| S:348 E:357 ||| NNS
and  ||| S:357 E:361 ||| CC
protein  ||| S:361 E:369 ||| NN
synthesis  ||| S:369 E:379 ||| NN
rates ||| S:379 E:384 ||| NNS
.  ||| S:384 E:386 ||| .
However ||| S:386 E:393 ||| RB
,  ||| S:393 E:395 ||| ,
whether  ||| S:395 E:403 ||| IN
protein  ||| S:403 E:411 ||| NN
and ||| S:411 E:414 ||| CC
/ ||| S:414 E:415 ||| NNP
or  ||| S:415 E:418 ||| CC
amino  ||| S:418 E:424 ||| JJ
acids  ||| S:424 E:430 ||| NNS
can  ||| S:430 E:434 ||| MD
modify  ||| S:434 E:441 ||| VB
the  ||| S:441 E:445 ||| DT
post  ||| S:445 E:450 ||| NN
exercise  ||| S:450 E:459 ||| NN
insulin  ||| S:459 E:467 ||| NN
responses  ||| S:467 E:477 ||| NNS
in  ||| S:477 E:480 ||| IN
horses  ||| S:480 E:487 ||| NNS
remains  ||| S:487 E:495 ||| VBZ
to  ||| S:495 E:498 ||| TO
be  ||| S:498 E:501 ||| VB
fully  ||| S:501 E:507 ||| RB
elucidated ||| S:507 E:517 ||| VBN
.  ||| S:517 E:519 ||| .
To  ||| S:519 E:522 ||| TO
determine  ||| S:522 E:532 ||| VB
whether  ||| S:532 E:540 ||| IN
whey  ||| S:540 E:545 ||| JJ
protein  ||| S:545 E:553 ||| NN
or  ||| S:553 E:556 ||| CC
leucine  ||| S:556 E:564 ||| JJ
addition  ||| S:564 E:573 ||| NN
to  ||| S:573 E:576 ||| TO
a  ||| S:576 E:578 ||| DT
glucose  ||| S:578 E:586 ||| JJ
solution  ||| S:586 E:595 ||| NN
affects  ||| S:595 E:603 ||| VBZ
the  ||| S:603 E:607 ||| DT
post  ||| S:607 E:612 ||| NN
gavage  ||| S:612 E:619 ||| VBZ
plasma  ||| S:619 E:626 ||| JJ
insulin ||| S:626 E:633 ||| NN
,  ||| S:633 E:635 ||| ,
glucose  ||| S:635 E:643 ||| NN
and  ||| S:643 E:647 ||| CC
amino  ||| S:647 E:653 ||| JJ
acid  ||| S:653 E:658 ||| NN
responses  ||| S:658 E:668 ||| NNS
in  ||| S:668 E:671 ||| IN
horses  ||| S:671 E:678 ||| NNS
and  ||| S:678 E:682 ||| CC
whether  ||| S:682 E:690 ||| IN
these  ||| S:690 E:696 ||| DT
responses  ||| S:696 E:706 ||| NNS
are  ||| S:706 E:710 ||| VBP
different  ||| S:710 E:720 ||| JJ
following  ||| S:720 E:730 ||| VBG
a  ||| S:730 E:732 ||| DT
period  ||| S:732 E:739 ||| NN
of  ||| S:739 E:742 ||| IN
exercise  ||| S:742 E:751 ||| NN
vs.  ||| S:751 E:755 ||| IN
rest ||| S:755 E:759 ||| NN
.  ||| S:759 E:761 ||| .
Six  ||| S:761 E:765 ||| CD
mature ||| S:765 E:771 ||| NN
,  ||| S:771 E:773 ||| ,
conditioned  ||| S:773 E:785 ||| VBN
Thoroughbreds  ||| S:785 E:799 ||| NNP
received  ||| S:799 E:808 ||| VBD
a  ||| S:808 E:810 ||| DT
nasogastric  ||| S:810 E:822 ||| JJ
gavage  ||| S:822 E:829 ||| NNS
containing  ||| S:829 E:840 ||| VBG
either  ||| S:840 E:847 ||| DT
1  ||| S:847 E:849 ||| CD
g ||| S:849 E:850 ||| FW
/ ||| S:850 E:851 ||| FW
kg  ||| S:851 E:854 ||| FW
bwt  ||| S:854 E:858 ||| FW
glucose  ||| S:858 E:866 ||| FW
( ||| S:866 E:867 ||| -LRB-
G ||| S:867 E:868 ||| NNP
) ||| S:868 E:869 ||| -RRB-
,  ||| S:869 E:871 ||| ,
G  ||| S:871 E:873 ||| NNP
+  ||| S:873 E:875 ||| FW
0.3  ||| S:875 E:879 ||| FW
g ||| S:879 E:880 ||| FW
/ ||| S:880 E:881 ||| FW
kg  ||| S:881 E:884 ||| FW
bwt  ||| S:884 E:888 ||| FW
whey  ||| S:888 E:893 ||| FW
protein  ||| S:893 E:901 ||| FW
( ||| S:901 E:902 ||| -LRB-
GW ||| S:902 E:904 ||| NNP
)  ||| S:904 E:906 ||| -RRB-
or  ||| S:906 E:909 ||| CC
G  ||| S:909 E:911 ||| NNP
+  ||| S:911 E:913 ||| FW
0.3  ||| S:913 E:917 ||| FW
g ||| S:917 E:918 ||| FW
/ ||| S:918 E:919 ||| FW
kg  ||| S:919 E:922 ||| FW
bwt  ||| S:922 E:926 ||| FW
leucine  ||| S:926 E:934 ||| FW
( ||| S:934 E:935 ||| -LRB-
GL ||| S:935 E:937 ||| NNP
) ||| S:937 E:938 ||| -RRB-
,  ||| S:938 E:940 ||| ,
following  ||| S:940 E:950 ||| VBG
a  ||| S:950 E:952 ||| DT
period  ||| S:952 E:959 ||| NN
of  ||| S:959 E:962 ||| IN
either  ||| S:962 E:969 ||| DT
rest  ||| S:969 E:974 ||| NN
( ||| S:974 E:975 ||| -LRB-
R ||| S:975 E:976 ||| NNP
)  ||| S:976 E:978 ||| -RRB-
or  ||| S:978 E:981 ||| CC
an  ||| S:981 E:984 ||| DT
exercise  ||| S:984 E:993 ||| NN
test  ||| S:993 E:998 ||| NN
on  ||| S:998 E:1001 ||| IN
a  ||| S:1001 E:1003 ||| DT
high  ||| S:1003 E:1008 ||| JJ
speed  ||| S:1008 E:1014 ||| NN
treadmill  ||| S:1014 E:1024 ||| NNS
( ||| S:1024 E:1025 ||| -LRB-
EX ||| S:1025 E:1027 ||| NNP
) ||| S:1027 E:1028 ||| -RRB-
.  ||| S:1028 E:1030 ||| .
Each  ||| S:1030 E:1035 ||| DT
horse  ||| S:1035 E:1041 ||| NN
was  ||| S:1041 E:1045 ||| VBD
studied  ||| S:1045 E:1053 ||| VBN
under  ||| S:1053 E:1059 ||| IN
all  ||| S:1059 E:1063 ||| DT
6  ||| S:1063 E:1065 ||| CD
treatment  ||| S:1065 E:1075 ||| NN
conditions ||| S:1075 E:1085 ||| NNS
,  ||| S:1085 E:1087 ||| ,
separated  ||| S:1087 E:1097 ||| VBN
by  ||| S:1097 E:1100 ||| IN
10  ||| S:1100 E:1103 ||| CD
day  ||| S:1103 E:1107 ||| NN
intervals ||| S:1107 E:1116 ||| NNS
.  ||| S:1116 E:1118 ||| .
Blood  ||| S:1118 E:1124 ||| NN
samples  ||| S:1124 E:1132 ||| NNS
were  ||| S:1132 E:1137 ||| VBD
collected  ||| S:1137 E:1147 ||| VBN
pre-exercise ||| S:1147 E:1159 ||| JJ
/ ||| S:1159 E:1160 ||| CD
rest ||| S:1160 E:1164 ||| NN
,  ||| S:1164 E:1166 ||| ,
pregavage  ||| S:1166 E:1176 ||| NN
and  ||| S:1176 E:1180 ||| CC
at  ||| S:1180 E:1183 ||| IN
regular  ||| S:1183 E:1191 ||| JJ
intervals  ||| S:1191 E:1201 ||| NNS
up  ||| S:1201 E:1204 ||| RB
to  ||| S:1204 E:1207 ||| TO
300  ||| S:1207 E:1211 ||| CD
min  ||| S:1211 E:1215 ||| JJ
post  ||| S:1215 E:1220 ||| NN
gavage ||| S:1220 E:1226 ||| NN
.  ||| S:1226 E:1228 ||| .
Plasma  ||| S:1228 E:1235 ||| NNP
was  ||| S:1235 E:1239 ||| VBD
analysed  ||| S:1239 E:1248 ||| VBN
for  ||| S:1248 E:1252 ||| IN
glucose  ||| S:1252 E:1260 ||| NN
and  ||| S:1260 E:1264 ||| CC
amino  ||| S:1264 E:1270 ||| JJ
acid  ||| S:1270 E:1275 ||| NN
concentrations  ||| S:1275 E:1290 ||| NNS
and  ||| S:1290 E:1294 ||| CC
serum  ||| S:1294 E:1300 ||| JJ
insulin  ||| S:1300 E:1308 ||| NN
concentrations  ||| S:1308 E:1323 ||| NNS
were  ||| S:1323 E:1328 ||| VBD
determined ||| S:1328 E:1338 ||| VBN
.  ||| S:1338 E:1340 ||| .
There  ||| S:1340 E:1346 ||| EX
was  ||| S:1346 E:1350 ||| VBD
a  ||| S:1350 E:1352 ||| DT
significantly  ||| S:1352 E:1366 ||| RB
( ||| S:1366 E:1367 ||| -LRB-
P  ||| S:1367 E:1369 ||| NNP
< ||| S:1369 E:1371 ||| SYM
0.05 ||| S:1371 E:1375 ||| CD
)  ||| S:1375 E:1377 ||| -RRB-
greater  ||| S:1377 E:1385 ||| JJR
insulin  ||| S:1385 E:1393 ||| NN
response  ||| S:1393 E:1402 ||| NN
in  ||| S:1402 E:1405 ||| IN
GL-R  ||| S:1405 E:1410 ||| JJ
and  ||| S:1410 E:1414 ||| CC
GL-EX  ||| S:1414 E:1420 ||| JJ
when  ||| S:1420 E:1425 ||| WRB
compared  ||| S:1425 E:1434 ||| VBN
to  ||| S:1434 E:1437 ||| TO
the  ||| S:1437 E:1441 ||| DT
other  ||| S:1441 E:1447 ||| JJ
treatments ||| S:1447 E:1457 ||| NNS
.  ||| S:1457 E:1459 ||| .
When  ||| S:1459 E:1464 ||| WRB
compared  ||| S:1464 E:1473 ||| VBN
to  ||| S:1473 E:1476 ||| TO
rest ||| S:1476 E:1480 ||| NN
,  ||| S:1480 E:1482 ||| ,
post  ||| S:1482 E:1487 ||| NN
exercise  ||| S:1487 E:1496 ||| NN
plasma  ||| S:1496 E:1503 ||| NN
glucose  ||| S:1503 E:1511 ||| NN
responses  ||| S:1511 E:1521 ||| NNS
were  ||| S:1521 E:1526 ||| VBD
lower  ||| S:1526 E:1532 ||| JJR
in  ||| S:1532 E:1535 ||| IN
G  ||| S:1535 E:1537 ||| NNP
and  ||| S:1537 E:1541 ||| CC
GW  ||| S:1541 E:1544 ||| NNP
but  ||| S:1544 E:1548 ||| CC
unchanged  ||| S:1548 E:1558 ||| JJ
following  ||| S:1558 E:1568 ||| VBG
GL  ||| S:1568 E:1571 ||| NNP
administration ||| S:1571 E:1585 ||| NN
.  ||| S:1585 E:1587 ||| .
Plasma  ||| S:1587 E:1594 ||| JJ
alanine  ||| S:1594 E:1602 ||| JJ
concentrations  ||| S:1602 E:1617 ||| NNS
were  ||| S:1617 E:1622 ||| VBD
elevated  ||| S:1622 E:1631 ||| JJ
post  ||| S:1631 E:1636 ||| NN
exercise  ||| S:1636 E:1645 ||| NN
in  ||| S:1645 E:1648 ||| IN
all  ||| S:1648 E:1652 ||| DT
EX  ||| S:1652 E:1655 ||| NNP
treatments ||| S:1655 E:1665 ||| NNS
.  ||| S:1665 E:1667 ||| .
With  ||| S:1667 E:1672 ||| IN
the  ||| S:1672 E:1676 ||| DT
exception  ||| S:1676 E:1686 ||| NN
of  ||| S:1686 E:1689 ||| IN
markedly  ||| S:1689 E:1698 ||| RB
elevated  ||| S:1698 E:1707 ||| VBD
plasma  ||| S:1707 E:1714 ||| JJ
leucine  ||| S:1714 E:1722 ||| JJ
concentrations  ||| S:1722 E:1737 ||| NNS
after  ||| S:1737 E:1743 ||| IN
GL-R  ||| S:1743 E:1748 ||| JJ
and  ||| S:1748 E:1752 ||| CC
GL-EX ||| S:1752 E:1757 ||| JJ
,  ||| S:1757 E:1759 ||| ,
the  ||| S:1759 E:1763 ||| DT
plasma  ||| S:1763 E:1770 ||| JJ
concentrations  ||| S:1770 E:1785 ||| NNS
of  ||| S:1785 E:1788 ||| IN
all  ||| S:1788 E:1792 ||| DT
indispensable  ||| S:1792 E:1806 ||| JJ
amino  ||| S:1806 E:1812 ||| NNS
acids  ||| S:1812 E:1818 ||| VBP
decreased  ||| S:1818 E:1828 ||| VBN
during  ||| S:1828 E:1835 ||| IN
the  ||| S:1835 E:1839 ||| DT
post  ||| S:1839 E:1844 ||| NN
gavage  ||| S:1844 E:1851 ||| NN
period ||| S:1851 E:1857 ||| NN
.  ||| S:1857 E:1859 ||| .
Leucine  ||| S:1859 E:1867 ||| NNP
but  ||| S:1867 E:1871 ||| CC
not  ||| S:1871 E:1875 ||| RB
whey  ||| S:1875 E:1880 ||| JJ
protein  ||| S:1880 E:1888 ||| NN
augmented  ||| S:1888 E:1898 ||| VBD
the  ||| S:1898 E:1902 ||| DT
serum  ||| S:1902 E:1908 ||| JJ
insulin  ||| S:1908 E:1916 ||| NN
response  ||| S:1916 E:1925 ||| NN
to  ||| S:1925 E:1928 ||| TO
an  ||| S:1928 E:1931 ||| DT
oral  ||| S:1931 E:1936 ||| JJ
glucose  ||| S:1936 E:1944 ||| JJ
load ||| S:1944 E:1948 ||| NN
.  ||| S:1948 E:1950 ||| .
Leucine  ||| S:1950 E:1958 ||| JJ
supplementation  ||| S:1958 E:1974 ||| JJ
warrants  ||| S:1974 E:1983 ||| NNS
further  ||| S:1983 E:1991 ||| JJ
investigation  ||| S:1991 E:2005 ||| NN
as  ||| S:2005 E:2008 ||| IN
a  ||| S:2008 E:2010 ||| DT
means  ||| S:2010 E:2016 ||| VBZ
to  ||| S:2016 E:2019 ||| TO
increase  ||| S:2019 E:2028 ||| VB
the  ||| S:2028 E:2032 ||| DT
rate  ||| S:2032 E:2037 ||| NN
of  ||| S:2037 E:2040 ||| IN
post  ||| S:2040 E:2045 ||| NN
exercise  ||| S:2045 E:2054 ||| NN
muscle  ||| S:2054 E:2061 ||| NN
glycogen  ||| S:2061 E:2070 ||| NN
synthesis  ||| S:2070 E:2080 ||| NN
in  ||| S:2080 E:2083 ||| IN
horses ||| S:2083 E:2089 ||| NNS
.  ||| S:2089 E:2091 ||| .
